Researchers develop antibody-targeted treatment for recurrent small-cell lung cancer

Researchers at Norris Cotton Cancer Center have found an antibody that may be used in future treatments for recurrent small-cell lung cancer, which currently has no effective therapy.

The mouse monoclonal antibody they have developed, MAG-1, targets the ProAVP surface marker. When given alone, it significantly slows the growth of tumor xenografts of human recurrent small-cell in mice. The study, "Growth Impairment of Small-Cell Cancer by Targeting Pro-Vasopressin with MAG-1 Antibody," was recently published online in Frontiers in Oncology.

"We are developing methods of antibody-targeted treatment for recurrent small-cell lung cancer," said lead author William G. North, PhD, professor of Physiology at the Geisel School of Medicine at Dartmouth and a member of the Norris Cotton Cancer Center. "Targeting with a humanized MAG-1 can likely be effective, especially when given in combination with chemotherapy, for treating a deadly disease for which there is no ."

North says his group has already generated a human chimeric form of MAG-1 that is equally effective as mouse MAG-1, and they are now generating a humanized form for use in patients.

Related Stories

Monoclonal antibody targets, kills leukemia cells

date Mar 25, 2013

Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells.

Recommended for you

Experts set strategic priorities for lymphoma research

date 11 hours ago

A committee of lymphoma experts today unveiled a strategic roadmap identifying key priority areas in both infrastructure and research that will be critical for advancing treatments for people with lymphoma. The report is meant to inform future research directions as well as fund ...

Research aims to reduce health care disparities

date 12 hours ago

The lesbian, gay, bisexual, transgender/transsexual, queer/questioning and intersex (LGBTQI) population has been largely understudied by the medical community. Researchers at Moffitt Cancer Center found that the LGBTQI community ...

Promising drug target identified in medulloblastoma

date 13 hours ago

Scientists at Dana-Farber/Boston Children's Cancer and Blood Disorders Center have identified a protein critical to both the normal development of the brain and, in many cases, the development of medulloblastoma, a fast-growing ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.